Nisoldipine controlled release tablet and preparation method thereof

A technology for nisoldipine and controlled-release tablets, which is applied in pill delivery, pharmaceutical formulations, medical preparations of non-active ingredients, etc., can solve problems such as low production efficiency, complicated three-layer tablet process, and large quality differences, and achieve production The effect of cost reduction, ease of scale-up production, and improvement of production efficiency

CN102406623AActive Publication Date: 2012-04-11SHANGHAI SUNTECH PHARMA +2
9 Cites 9 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2012-04-11

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a nisoldipine controlled release tablet which comprises micronized nisoldipine and medicinal auxiliary materials, wherein the medicinal auxiliary materials include surfactants, pH-dependent auxiliary materials, water-soluble gel materials and / or water-insoluble gel materials, filling agents and lubricating agents. The nisoldipine controlled release tablet provided by the invention is a simple single-layer tablet of which the prescription and preparation method are simpler than those of the existing nisoldipine controlled release tablets such as core-spun tablets and three-layer tablets. The nisoldipine controlled release tablet can be prepared by using equipment for preparing common tablets without using special equipment, thereby improving the production efficiency and lowering the production cost. The release rate of the nisoldipine controlled release tablet provided by the invention in different pH environments can be controlled, and the tablet is stable.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of pharmaceutical formulations, in particular to a controlled-release tablet of nisoldipine and a preparation method thereof. Background technique

[0002] Calcium channel blockers are a class of heterologous drugs that prevent or slow the entry of calcium into cells by modulating cellular calcium channels. It is of great significance to the regulation of calcium entry into cells of the cardiovascular system and the normal operation of the system. Cardiac and vascular smooth muscle cells have calcium channels located within the cell membrane. Calcium flows into the cell through these channels, initiating an electromechanical coupling process that ultimately causes muscle contraction. Regulating the ability of calcium to enter the heart and vascular smooth muscle is a powerful treatment for angina and high blood pressure.

[0003] Nisoldipine, a dihydropyridine calcium channel blocker, is a yellow crystalline substa...

Examples

Embodiment 1

[0047] Example 1 Dissolution test of nisoldipine obtained by various treatment methods

[0048] Nisoldipine is almost insoluble in water, and its solubility in water is determined to be only 0.000036 mg / ml.

[0049] 1. Treat nisoldipine as follows:

[0050] (1) non-micronized conventional preparation powder;

[0051] (2) carry out micronization treatment with nisoldipine by conventional method;

[0052] (3) according to the inventive method described above, carry out micronization treatment after nisoldipine and sodium lauryl sulfate are uniformly dispersed together;

[0053] (4) according to the inventive method described above, first carry out micronization treatment with nisoldipine, then handle with sodium lauryl sulfate solution;

[0054] (5) The nisoldipine and sodium lauryl sulfate are respectively micronized by a conventional method.

[0055] 2. The nisoldipine that is not micronized, the nisoldipine that is micronized separately, and the micronized nisoldipine tha...

Embodiment 2

[0067] The effect of embodiment 2 micronization on the release rate of nisoldipine

[0068] After solving the dissolution rate of nisoldipine, the key is to solve the release mode and release rate of nisoldipine controlled-release tablets. Patents US20080063711, US20080057123, US20080221174, CN200780034924.1, WO2008025532 improved the bioavailability by changing the release site of nisoldipine compared with patents US5422123 and US5626874, because the bioavailability of nisoldipine was only about 5%. There is intestinal wall metabolism in the intestinal tract, and it is less metabolized in the lower part of the intestinal tract than in the upper part of the intestinal tract. The existing patent controls the release area of ​​the tablet during initial release through the three-layer tablet technology and uses pH-dependent excipients to control the release of nisoldipine in various parts of the digestive tract.

[0069] The inventors used a single-layer tablet containing pH-dep...

Embodiment 3

[0114] Example 3 Release comparison of different doses of nisoldipine formulations in buffered saline solutions with different pH 6.8 values

[0115] Prescription D (per 1000 tablets):

[0116] Nisoldipine 8.5g 3.7%

[0117] Sodium Lauryl Sulfate 8.5g 3.7%

[0118] Acrylic resin 10g 4.4%

[0119] Hypromellose 95g 41.5%

[0120] Lactose 103g 45.0%

[0121] Micronized silica gel 2.5g 1.1%

[0122] Magnesium Stearate 1.25g 0.6%

[0123] Total solids 228.75 100.0%

[0124] Preparation process: same as prescription A.

[0125] Prescription E (per 1000 tablets):

[0126] Nisoldipine 25.5g 9.5%

[0127] Sodium Lauryl Sulfate 31.875g 11.8%

[0128] Acrylic resin 10g 3.7%

[0129] Hypromellose 95g 35.3%

[0130] Lactose 103g 38.3%

[0131] Micropowder silica gel 2.5g 0.9%

[0132] Magnesium Stearate 1.25g 0.5%

[0133] Total solids 269.125 100%

[0134] Preparation process: same as prescription A.

[0135] Prescription F (per 1000 tablets):

[0136] Nisoldipine 34g 11...